Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent

We assessed the use of quantitative clinical and pathologic information to predict which patients would eventually require treatment for prostate cancer (CaP) in an expectant management (EM) cohort.

[1]  P H Bartels,et al.  Computer‐generated diagnosis and image analysis. An Overview , 1992, Cancer.

[2]  R W Veltri,et al.  Quantitative nuclear grade (QNG): A new image analysis‐based biomarker of clinically relevant nuclear structure alterations , 2000, Journal of cellular biochemistry. Supplement.

[3]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[4]  R W Veltri,et al.  Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. , 2000, Urology.

[5]  P. Walsh,et al.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. , 2002, The Journal of urology.

[6]  P. Humphrey,et al.  Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. , 1996, The Journal of urology.

[7]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[8]  D. Bostwick,et al.  Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer. , 1999, Seminars in urologic oncology.

[9]  Robert W Veltri,et al.  Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy , 2003, Cancer.

[10]  D. Tindall,et al.  p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. , 2005, Cancer research.

[11]  R W Veltri,et al.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. , 1999, Urology.

[12]  D. Grignon,et al.  Prostate cancer: indicators of aggressiveness. , 1997, European urology.

[13]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[14]  Alan W Partin,et al.  Characteristics of insignificant clinical T1c prostate tumors , 2004, Cancer.

[15]  P. Walsh,et al.  Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. , 1997, Journal of Urology.

[16]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[17]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[18]  D. S. Coffey,et al.  Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer , 1982, The Prostate.

[19]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[20]  T. Stamey,et al.  Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. , 1998, The Journal of urology.

[21]  K. Pienta,et al.  Identification of nuclear matrix proteins in the cancer and normal rat prostate. , 1991, Cancer research.

[22]  D C Young,et al.  An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. , 1996, The Journal of urology.

[23]  M. Allaf,et al.  Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. , 2006, Urologic oncology.

[24]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[25]  D. Tindall,et al.  p300 modulates nuclear morphology in prostate cancer. , 2005, Cancer research.

[26]  S. Razin,et al.  Analysis of the chicken DNA fragments that contain structural sites of attachment to the nuclear matrix: DNA–matrix interactions and replication , 2000, Journal of cellular biochemistry.

[27]  J. Gill,et al.  Further observations on the chemistry of Pararosaniline-Feulgen staining , 1976, Histochemistry.

[28]  M. Kattan,et al.  How to judge a tumor marker , 2005, Nature Clinical Practice Oncology.

[29]  A W Partin,et al.  A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. , 1989, The Journal of urology.

[30]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[31]  B Palcic,et al.  Nuclear texture: can it be used as a surrogate endpoint biomarker? , 1994, Journal of cellular biochemistry. Supplement.

[32]  D. Wittekind,et al.  Standardization of the Feulgen-Schiff technique , 2004, Histochemistry.

[33]  M. Allaf,et al.  Update on watchful waiting for prostate cancer , 2004, Current opinion in urology.

[34]  A. Partin,et al.  Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease‐free survival among patients with prostate cancer , 1992, Cancer.

[35]  Robert W Veltri,et al.  Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. , 2002, The Journal of urology.

[36]  A. Partin,et al.  Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. , 2001, Urology.

[37]  Daniel J Schaid,et al.  The complex genetic epidemiology of prostate cancer. , 2004, Human molecular genetics.

[38]  D. Chan,et al.  Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. , 2003, The Journal of urology.

[39]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[40]  E. Bergstralh,et al.  Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. , 1999, Urology.

[41]  G S Stein,et al.  Nuclear structure-gene expression interrelationships: implications for aberrant gene expression in cancer. , 2000, Cancer research.

[42]  P. Spiess,et al.  Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer , 2006, Cancer.

[43]  A. Partin,et al.  Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? , 2003, The Journal of urology.

[44]  Jonathan I. Epstein,et al.  Ability to Predict Metastasis Based On Pathology Findings and Alterations in Nuclear Structure Of Normal-Appearing and Cancer Peripheral Zone Epithelium in the Prostate , 2004, Clinical Cancer Research.